Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial
Diabetes Care · 2025
DOI: 10.2337/dc24-1597 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2025. Verfasst von Patrizia Pasanisi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. Hauptthemen laut MEDLINE: Diet, Mediterranean, Metformin, Metabolic Syndrome, Hypoglycemic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FP7 Ideas: European Research Council.
Abstract (Originalsprache)
OBJECTIVE The Metformin and Dietary Restriction to Prevent Age-Related Morbid Events in People With Metabolic Syndrome (MeMeMe) trial tested whether 1,700 mg/day metformin (MET) with or without a Mediterranean diet (MedDiet) intervention could reduce the cumulative incidence of major noncommunicable diseases in people with metabolic syndrome. RESEARCH DESIGN AND METHODS A total of 1,442 participants were randomly assigned to one of four interventions: 1) MET (1,700 mg/day) plus MedDiet intervention (MET+MedDiet); 2) placebo plus MedDiet intervention; 3) MET (1,700 mg/day) alone; and 4) placebo alone. Participants were followed up for 3 years on average. The primary outcome was the cumulative incidence of major noncommunicable diseases (including type 2 diabetes, cardiovascular diseases, and cancer). Secondary outcomes were the incidence of type 2 diabetes and the changing prevalence of metabolic syndrome. RESULTS The crude incidence of the major noncommunicable diseases was 6.7 cases per 100 person-years in the MET+MedDiet group, 6.9 in the MET alone group, 13.3 in the placebo plus MedDiet group, and 11.3 in the placebo group. The differences were fully explained by the reduction of type 2 diabetes, which was 80% and 92% lower in the MET and MET+MedDiet groups, respectively, compared with placebo. CONCLUSIONS The use of 1,700 mg/day MET is effective to prevent diabetes in people selected on the basis of metabolic syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
- Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
- Department of Advanced Diagnostic Services, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
- Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada.
- Department of Medicine, Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada.
- Department of Biomedical Sciences, Humanitas University, Milano, Italy.
ORCID-Profile: Ivan Baldassari
Förderung
- FP7 Ideas: European Research Council
Zitieren
APA
Pasanisi, P., Oliverio, A., Baldassari, I., Bruno, E., Venturelli, E., Bellegotti, M., Gargano, G., Morelli, D., Bognanni, A., Rigoni, M., Muti, P., & Berrino, F. (2025). Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial. Diabetes Care. https://doi.org/10.2337/dc24-1597
Vancouver
Pasanisi P, Oliverio A, Baldassari I, Bruno E, Venturelli E, Bellegotti M, et al. Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial. Diabetes Care. 2025. doi:10.2337/dc24-1597
BibTeX
@article{Pasanisi2025,
author = {Pasanisi, Patrizia and Oliverio, Andreina and Baldassari, Ivan and Bruno, Eleonora and Venturelli, Elisabetta and Bellegotti, Manuela and Gargano, Giuliana and Morelli, Daniele and Bognanni, Antonio and Rigoni, Marta and Muti, Paola and Berrino, Franco},
title = {Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial},
journal = {Diabetes Care},
year = {2025},
doi = {10.2337/dc24-1597}
}
EUVIMED